north carolina

During the first half of the year, the revenues of the Catalan multinational pharmaceutical company Grifols rose by 16.7% to €1.61 bilion, 75% of which came from the Bioscience division and 18% from Diagnostic. Compared to the first quarter, the proportion of total sales generated by each of the group’s divisions remains unchanged after the acquisition of Novartis' diagnostic business. The world´s third-largest blood-derivate product maker, Grifols obtained a net profit of €224.8 million, 23% more compared with the same period last year, as reported by the company to the Spanish Stock Exchange Authority (CNMV). These positive figures were achieved due to the maintenance of financial costs, made possible by improved financial conditions, despite having increased debt in absolute terms.

A plasma fractionation plant installed in Clayton, North Carolina by the company Grífols was unveiled on Tuesday by the President of the Catalan Government, Artur Mas, along with the President and CEO of the pharmaceutical, Víctor Grífols, and the State Governor, Pat McCrory. The new plant is 14,400 square metres big, will create over 200 jobs and represents an investment of 260 million euros. Expected to be operational by 2015, it will the largest and one of the most advanced plasma fractionation plants in the world. Grífols already has 2,300 employees in the state of North Carolina and it is among the world's top pharmaceuticals within the blood-derivates market. A few weeks ago, Víctor Grífols gave his support to the Catalan President and the self-determination process, which he confirmed on Tuesday.